ACAD ACADIA PHARMACEUTICALS INC

Ownership history in Birchview Capital, LP  ·  27 quarters on record

This page tracks every 13F SEC filing in which Birchview Capital, LP reported a position in ACADIA PHARMACEUTICALS INC (ACAD). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
5.9% (2023 Q4)
Avg. % of fund
3.15%
First filed
2019 Q2
Last filed
2025 Q4
Quarters held
27
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 UNCHANGED 171,000 0% 2.67% $4.6M $26.71
2025 Q3 REDUCED 171,000 -16,800 -8.9% 2.76% $3.6M $21.34
2025 Q2 REDUCED 187,800 -75,600 -28.7% 4.02% $4.1M $21.57
2025 Q1 REDUCED 263,400 -75,000 -22.2% 3.80% $4.4M $16.61
2024 Q4 REDUCED 338,400 -62,000 -15.5% 5.06% $6.2M $18.35
2024 Q3 ADDED 400,400 +150,000 +59.9% 5.34% $6.2M $15.38
2024 Q2 UNCHANGED 250,400 0% 3.77% $4.1M $16.25
2024 Q1 ADDED 250,400 +10,000 +4.2% 3.78% $4.6M $18.49
2023 Q4 UNCHANGED 240,400 0% 5.90% $7.5M $31.31
2023 Q3 REDUCED 240,400 -9,000 -3.6% 4.26% $5.0M $20.84
17 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    ACAD price (monthly, adj. close)
← Back to Birchview Capital, LP Holdings